Nature Medicine
This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection – the Antibody Mediated Prevention (AMP) trials
A new biomarker appears to be an effective surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium
Multiple non-endemic countries were recently hit by a monkeypox virus outbreak. While most cases present with lesions in the anogenital region, it is unclear whether asymptomatic or otherwise undiagnosed infections are fuelling this epidemic.
Composition of the gut microbiome is associated with response and toxicity following anti-CD19 CAR T cell therapy
The intestinal microbiome is associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B-cell malignancies.
When your body attacks itself – BTK inhibition shows promise for the treatment of chronic spontaneous urticaria (an autoimmune disease)
In a recent clinical trial, patients who had chronic spontaneous urticaria (CSU) for more than 6 months that would not respond to high doses of standard treatment (H1-antihistamines) – were enrolled to evaluate a “BTK blocker” drug, called, "fenebrutinib".
The emergence of neutralizing antibodies limits success of mycobacteriophage therapy
Mycobacterium abscessus infections present a major challenge to antibiotic therapy. Bacteriophages have a potential role to play in treatment of these infections, but neutralizing antibody reactions can limit the efficacy of the phages when administered intravenously.
Operationalizing genomic epidemiology during the Nord Kivu Ebola outbreak, Democratic Republic of Congo
In July 2018, the National Biomedical Research Institute (INRB), in the Democratic Republic of Congo (DRC), set up a pathogen genomics laboratory which allowed us to confirm epidemics of Ebola Virus Disease in the country and to establish epidemiological links between confirmed cases (1-3).
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer patients: the NABUCCO trial
This blog reflects on the journey that led to the publication of our preoperative combination immunotherapy study in Nature Medicine.
Zero Childhood Cancer – an Australian national precision medicine program for high-risk pediatric cancer
What value does deciphering the whole genome hold for guiding clinical care of children with high-risk cancer? Does it provide more accurate diagnoses, more treatment options, better risk stratification? Can it be analyzed fast enough to have real-time clinical impact?
